The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for daratumumab, marketed by Janssen as Darzalex. If approved by the European Commission,...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ml9pT1
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Purpose. To evaluate the diagnostic performance of the McMonnies questionnaire as a screening survey for dry eye in Chinese outpatients. Met...
-
Abstract Background With the development of emergency and intensive medical technologies, the survival rate of traumatic brain injury ha...
-
Papillary squamous cell carcinoma of the palatine tonsil: a rare cancer of the head and neck. Acta Otorhinolaryngol Ital. 2017 May 22;...
-
Background: Paget disease, Bowen disease, and malignant melanoma in situ are intraepidermal neoplasms, characterized by the presence of page...
-
Abstract Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic l...
-
Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of mortality in patients with neurofibromatosis type 1. In 2002, an MPN...
-
The pursuit for clarity in diagnostic and treatment pathways for the complex, chronic condition of myalgic encephalomyelitis/chronic fatigue...
-
We present a case of a patient with diabetes with a pleural empyema originated from a pyomyositis process established after a central line p...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου